Sugammadex ED90 dose to reverse the rocuronium neuromuscular blockade in obese patients

Mauro Prado DA Silva1, Christiano Matsui1, Daniel Dongiou Kim1

  • 1- Central Hospital, Brotherhood of the Santa Casa de Misericórdia de São Paulo, Sevice of Anesthesiology, Sao Paulo, São Paulo State, Brazil.

Abstract

Insights

The minimum effective dose (ED90) of sugammadex for reversing moderate neuromuscular blockade induced by rocuronium in obese patients undergoing bariatric surgery was determined to be 2.39 mg/kg.

Area of Science:

  • Anesthesiology
  • Pharmacology

Background:

  • Neuromuscular blockade (NMB) reversal is critical in surgery.
  • Obesity can affect drug pharmacokinetics, potentially altering NMB reversal efficacy.

Purpose of the Study:

  • To determine the ED90 (minimum effective dose in 90% of patients) of sugammadex for reversing rocuronium-induced moderate NMB.
  • To evaluate sugammadex efficacy in patients with grade III obesity undergoing bariatric surgery.

Main Methods:

  • Prospective study utilizing a biased coin up-and-down sequential design.
  • Rocuronium 0.6 mg/kg was administered, with sugammadex doses ranging from 2.0 to 2.8 mg/kg.
  • Complete NMB reversal was defined as a T4/T1 ratio ≥0.9, measured by TOF.

Main Results:

  • 31 patients were evaluated; 26 showed successful reversal, and 5 experienced failure.
  • The mean time to complete NMB reversal was 213 seconds.
  • The calculated ED90 of sugammadex was 2.39 mg/kg (95% CI: 2.27-2.46 mg/kg).

Conclusions:

  • The ED90 of sugammadex for reversing moderate rocuronium-induced NMB in patients with grade III obesity is 2.39 mg/kg.
  • Sugammadex demonstrates effective reversal of NMB in this specific patient population.

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
316
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.1K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
672
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
962
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
1.1K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
867